Sen. Richard Blumenthal (D-Conn.) is calling on the Department of Justice (DOJ) to reject a settlement with the maker of EpiPens and instead press on with its investigation of the company, Mylan.

ADVERTISEMENT

Blumenthal's call comes after an announcement by Mylan earlier this month that it had reached a $465 million settlement with the DOJ over claims that the company overcharged the Medicaid program for years by misclassifying EpiPens as the wrong type of drug.

The settlement, however, involved no admission of wrongdoing by Mylan, and Blumenthal cited estimates that the company could have overcharged by more than $700 million.

“A settlement that lacks any acknowledgement of responsibility and requires payment smaller than profits made illegally at taxpayer expense is simply unacceptable,” Blumenthal wrote in a letter to the DOJ.

“The American people have been rightly outraged by Mylan’s apparent profiteering and price gouging and possible fraud,” he said. “DOJ must fulfill its responsibility to fully and fairly investigate the facts, establish intent, and punish wrongdoing to deter present and future bad actors.”

Mylan has been the subject of outrage on both sides of the aisle recently for its more than 400 percent price increases in recent years for its life-saving allergy treatment.

Senate Judiciary Committee Chairman Chuck Grassley Charles (Chuck) Ernest GrassleyCollins says she will vote 'no' on Supreme Court nominee before election The Hill's Morning Report - Sponsored by Facebook - Trump, GOP allies prepare for SCOTUS nomination this week Gardner signals support for taking up Supreme Court nominee this year MORE (R-Iowa) has pressed the DOJ for details of the settlement.